Compare Gilead Sciences, Inc. (GILD) vs Open Text Corporation (OTEX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Open Text Corporation — how do they compare? Gilead Sciences, Inc. trades at $134.76 (market cap $163.51B), while Open Text Corporation trades at $23.47 (market cap $5.45B). The key difference: Gilead Sciences, Inc. is far larger — about 30× Open Text Corporation's market cap, and Open Text Corporation pays the higher dividend (4.84%). Which is the better fit depends on your goals.
| GILD | OTEX | |
|---|---|---|
Market Cap | $163.51B | $5.45B |
Sector | Health | Technology |
52-Week High | $155.80 | $39.69 |
52-Week Low | $108.22 | $20.01 |
Enterprise Value | $178.05B | $10.61B |
Dividend Yield | 2.49% | 4.84% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $133.30, up 2.51% today, with strong technical momentum above key support at $130. The company demonstrates robust fundamentals with a 30.99% net income margin and consistent earnings beats in recent quarters. Recent FDA and EC approvals for Trodelvy in metastatic triple-negative breast cancer highlight growth potential beyond its HIV franchise.
Outlook remains positive with a consensus price target of $152.83 offering 14.6% upside, though risks include patent expirations and competitive pressures. The stock presents a compelling opportunity driven by oncology expansion and strong cash flow generation, supported by overwhelming analyst bullish sentiment.
OpenText (OTEX) trades at $22.76, showing modest daily gains. The stock presents a mixed picture: technical indicators are bearish, but fundamental valuation metrics appear attractive with a P/E of 11.04 and EV/EBITDA of 6.63. The company has consistently beaten earnings expectations in recent quarters and is executing a strategic shift, divesting non-core assets like Vertica while investing in AI and cloud capabilities in Europe. Operating cash flow remains strong at $831M for 2025.
The outlook is cautiously optimistic. The primary opportunity lies in the stock's apparent undervaluation relative to its cash flow and the strategic repositioning towards high-growth AI and cloud segments. Key risks include execution of the new CEO's organic growth plan, competitive pressures in enterprise software, and the stock's current bearish technical momentum which may persist in the near term.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Open Text Corporation
Open Text Corporation is a global leader in Enterprise Information Management (EIM) software and solutions. The company provides a comprehensive platform that helps organizations manage, secure, and leverage their unstructured digital content, including documents, emails, and media files. OTEX's offerings span content management, business process management, customer experience management, and security, serving large enterprises across various industries worldwide.
Read more on OTEX →
